CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: January 5, 2017
Result type: Reports
Project Number: SE0513-000
Product Line: Reimbursement Review

Generic Name: Etanercept

Brand Name: Erelzi

Manufacturer: Sandoz Canada Inc.

Therapeutic Area: Rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis

Indications: Ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, rheumatoid arthritis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: July 25, 2017

Recommendation Type: Reimburse with clinical criteria and/or conditions